Remap Consulting

🌋 𝐀 𝐬𝐞𝐢𝐬𝐦𝐢𝐜 𝐬𝐡𝐢𝐟𝐭 𝐢𝐧 𝐄𝐔 𝐇𝐓𝐀 𝐢𝐬 𝐣𝐮𝐬𝐭 𝐚𝐫𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐜𝐨𝐫𝐧𝐞𝐫—𝐚𝐫𝐞 𝐲𝐨𝐮 𝐫𝐞𝐚𝐝𝐲? With EU-wide health technology assessments for oncology products and ATMPs kicking off in under 12 weeks, manufacturers face a critical need to navigate this monumental change. Our latest research sheds light on key trends in value demonstration and practical strategies to help you prepare for this new era in market access. Join Consultant Lauren Boland at #ISPOREurope for a deep dive into the complexities of EU HTA and discover how we can help turn your strategy into action. Don’t miss our discussion hour on Tuesday 19th November, from 12:30 to 1:30 pm. Meet our #EUHTA experts, Dr Paul Craddy and Dr Graham Foxon at 📍𝐛𝐨𝐨𝐭𝐡 𝟏𝟏𝟏𝟑 or schedule a conversation at contact@remapconsulting.com. Check out our full conference programme on our dedicated page 👉 https://lnkd.in/eSEUQy8D #EUHTA #HEOR #MarketAccess #HealthTechnology #PatientAccess #Pharma #Healthcare #ValueAssessments #JointClinicalAssessments

⏳𝐋𝐀𝐒𝐓 𝐂𝐇𝐀𝐍𝐂𝐄 𝐓𝐎 𝐑𝐄𝐆𝐈𝐒𝐓𝐄𝐑 for our upcoming webinar on Joint Scientific Consultation! This is a unique opportunity to dive deep into the intricacies of Joint Scientific Consultation with real questions from the field. From timelines and processes to the impact on launch success and eligibility criteria, our experts are ready to answer the questions that matter to you. ❓ Some of the questions submitted by registrants include: • What are the expected challenges for orphan drugs? • How can we maximise the value of JSC for planning JCA procedures? • What are the best strategies for successful dossier preparation? Don’t miss out on an opportunity to gain actionable guidance and strategies. 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰 ➡ https://lnkd.in/e44p-D9h #MarketAccess #PatientAccess #webinar #onlinelearning #jointscientificconsultation #jointclinicalassessment #euhta #oncology #pharma #healthcare

💡 As healthcare pivots towards proactive care, Remap Consulting's Amrit Kaliasethi and Tia Kwong have undertaken a study on proactive risk surveillance. Their research for #ISPOREurope explores new strategies for anticipating and reducing risks in heart failure and stroke, unlocking the potential of diverse data for smarter, patient-centered decisions. Attending ISPOR? Don't miss the chance to discuss this approach with Practice Lead Mariam Bibi on Tuesday 19th November, from 12:30 to 1:30 pm. Plus, meet the rest of our #pricing and #marketaccess experts at 📍 𝐛𝐨𝐨𝐭𝐡 𝟏𝟏𝟏𝟑 or pre-book a meeting at contact@remapconsulting.com. #HEOR #Healthcare #RiskManagement #DataInnovation #ProactiveCare #PatientCare #Pharma #Patients

Has it been a week already? 🌎 At this year's World Orphan Drug Congress Europe, our team saw first-hand how the industry is bracing for key changes and innovations that will define 2025 and beyond. From navigating the EU HTA rollout to harnessing real-world data and amplifying patient voices, the congress highlighted essential strategies for the evolving rare disease landscape.   Catch our latest report for key insights:   🔹 Strategic insights from our panel on “Evidence Generation for Multiple Stakeholder Needs” 🔹 Perspectives on industry readiness for EU HTA implementation 🔹 Key takeaways from all the keynotes 🔹 New research on early access frameworks and specialised tech from our team at Remap   Curious about the latest in rare disease access? Click to read our report! 📖 🔗 https://lnkd.in/e4zQcdic   What was your #WODC2024 highlight? Share your thoughts in the comments!   #marketaccess #EUHTA #raredisease #orphandrugs #pharmaceuticals #healthcare #patientaccess

We’d like to extend a heartfelt thanks to our #WODC panellists - Dr. Ruth Pulikottil Jacob, Andrew Olaye, Daniel de Vicente and Josie Godfrey for their invaluable insights and for taking the time to share their perspectives on the unique challenges of evidence generation in rare diseases. “𝘉𝘳𝘪𝘯𝘨𝘪𝘯𝘨 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘴𝘶𝘤𝘩 𝘱𝘢𝘴𝘴𝘪𝘰𝘯𝘢𝘵𝘦 𝘷𝘰𝘪𝘤𝘦𝘴 𝘳𝘦𝘮𝘪𝘯𝘥𝘴 𝘶𝘴 𝘸𝘩𝘺 𝘱𝘢𝘵𝘪𝘦𝘯𝘵-𝘤𝘦𝘯𝘵𝘦𝘳𝘦𝘥 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘪𝘯 𝘳𝘢𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴 𝘢𝘳𝘦 𝘦𝘴𝘴𝘦𝘯𝘵𝘪𝘢𝘭," said Practice Lead Mariam Bibi, reflecting on the lively discussion. 🎥 Pop the sound on and watch the snippet below, where Josie discusses her experience across diverse global regions, emphasising how crucial cultural sensitivity is in patient engagement. From the UK to Russia, Singapore, and beyond, she explores alternative ways to ensure patient voices are heard; especially where direct advocacy is challenging. By collaborating with clinical communities and local groups, she illustrates how we can capture what matters most to patients, even when engagement takes a different path. 📄 For a deeper dive into the full panel discussion, check out our comprehensive session notes here ➡ https://lnkd.in/ecnGQDqE #MarketAccess #PatientAccess #Pharma #RareDiseases #PatientsFirst #EvidenceGeneration #HealthcareInnovation #WODC

🔍 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐀𝐓𝐌𝐏𝐬 𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞𝐢𝐫 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐯𝐚𝐥𝐮𝐞 𝐭𝐨 𝐩𝐚𝐲𝐞𝐫𝐬? With the rapid rise of advanced therapy medicinal products (ATMPs), demonstrating a compelling economic case has never been more crucial. Our third piece of research for this year's conference dives into strategies for ATMPs to showcase their value effectively, featuring real-world insights that payers need today. At #ISPOREurope 2024, Paul Craddy will host a discussion hour, where you can explore these findings and discuss their implications for future market access. 📅 Join us on Tuesday 𝟏𝟗𝐭𝐡 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫, from 𝟏𝟐:𝟑𝟎 𝐭𝐨 𝟏:𝟑𝟎 𝐩𝐦 for this essential session that bridges innovation and access. Read the abstract here 👉 https://lnkd.in/e2kE9uvm #MarketAccess #HEOR #ATMPs #RealWorldEvidence #Pharma #Healthcare ISPOR—The Professional Society for Health Economics and Outcomes Research

That's a wrap on the World Orphan Drug Congress Europe 2024! 🏁 With the stand packed away and our team on their way home, we’re reflecting on an inspiring week filled with discussions, learning, and insights from across the #raredisease landscape. Day 3 concluded with keynotes on 'Real-World Data (RWD) in orphan drug development' and 'Building a Sustainable Pipeline for Gene Therapies'. These sessions highlighted the importance of collaboration, patient-centric outcomes, and regulatory advancements 🧬 𝐆𝐨𝐭 𝟔𝟎 𝐬𝐞𝐜𝐨𝐧𝐝𝐬? Check out the key takeaways here: https://lnkd.in/epkGj8UX 📥 Plus, our full conference report—covering insights from the Access & Pricing and Real-World Evidence tracks, as well as Mariam’s panel on evidence generation—will be available next week. Stay tuned! #WODC2024 #MarketAccess #PatientAccess #Pharma #OrphanDrugs #EUHTA #Healthcare #GeneTherapy

It’s the final day of #WODC2024, and our team are making the most of every moment! ⭐ With a wealth of experience in generating real-world insights from healthcare stakeholders across Europe, Senior Consultant Amrit is looking forward to this morning’s keynote, ‘The Use of Real-World Data in Orphan Drug Development and Access Pathways.’ Stay tuned for his key takeaways in our afternoon update! 📍 Be sure to stop by 𝐬𝐭𝐚𝐧𝐝 𝟔𝟐 to connect with our team and discuss your patient access and pricing challenges before you leave Barcelona. Not attending the conference? Subscribe to our newsletter to catch the highlights from day 3! 📰 https://lnkd.in/exy8iWT6 #WODC2024 #RareDiseases #MarketAccess #PatientAccess #Pharma #OrphanDrugs #EUHTA #Healthcare

What a jam-packed day at Fira de Barcelona! 🎉 Day 2 at the World Orphan Drug Congress Europe 2024 brought compelling insights from expert speakers during two fascinating keynotes, focused on the rare disease integration and patient centricity. 🔑 Key takeaway from the 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐀𝐜𝐭𝐢𝐨𝐧 𝐏𝐥𝐚𝐧 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The panel explored how national and EU-level strategies can align to create real impact in rare disease policies. The focus was on collaboration, learning from countries already implementing action plans, and closing gaps in patient care and drug development. 🔑 Key takeaway from the 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐕𝐨𝐢𝐜𝐞 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The discussion underscored the increasing importance of patient involvement in shaping policy and clinical trials for rare diseases. While progress has been made, the need to formalise patient engagement and involve them earlier is critical to ensure trials and policies truly reflect patient experiences. 📥 Want the full report? Download it here ➡ https://lnkd.in/e4zQcdic #WODC2024 #RareDiseases #PatientAccess #Healthcare #MarketAccess #Pharma #EUHTA #Patients #OrphanDrugs

🗣️ In just a few minutes, Mariam Bibi will take the stage in Theatre 6 at #WODC, alongside our distinguished guest speakers Dr. Ruth Pulikottil Jacob, Andrew Olaye, Josie Godfrey and Daniel de Vicente. This panel will explore how evidence generation strategies can help improve patient access, shape decision-making, and meet the diverse needs of payers, healthcare providers, and patient organisations. Expect a deep dive into the challenges and opportunities in generating strong evidence that supports HTA submissions and demonstrates value in the complex world of rare disease treatments. 🚀 If you’re at the conference, don’t miss this insightful session! Head to Theatre 6 and join the conversation. Plus, keep an 👀 on LinkedIn later today for our "WODC in 60 seconds" daily recap! 📅 24th October📍 Panel Discussion: "Strategic Evidence Generation: Exploring Multiple Stakeholder Needs" #EvidenceGeneration #PatientAccess #RareDiseases #HTA #HealthcareInnovation #OrphanDrugs #StakeholderEngagement World Orphan Drug Congress Europe